Want to see TEVA full AI Analyst Report?

Teva (TEVA) Price & Analysis

48 Followers

TEVA Stock Chart & Stats

$38.10

-$0.37(-1.19%)

At close: Jul 24 4:00 PM EDT

$38.10

-$0.37(-1.19%)

Day’s Range― - ―

52-Week Range$16.74 - $42.02

Previous CloseN/A

Volume3.13M

Average Volume (3M)5.98M

Market Cap

$47.21B

Enterprise Value$154.00B

Total Cash (Recent Filing)$3.63B

Total Debt (Recent Filing)$16.76B

Price to Earnings (P/E)67.3

Beta-0.52

Next Earnings

Nov 03, 2026

EPS Estimate

0.73

Next Dividend Ex-DateN/A

Dividend Yield5.8%

Share Statistics

EPS (TTM)0.63

Shares Outstanding1,165,296,100

10 Day Avg. Volume6,236,085

30 Day Avg. Volume5,981,074

Financial Highlights & Ratios

PEG Ratio-0.14

Price to Book (P/B)4.58

Price to Sales (P/S)1.94

P/FCF Ratio14.18

Enterprise Value/Market Cap3.26

Enterprise Value/Revenue8.85

Enterprise Value/Gross Profit16.87

Enterprise Value/Ebitda49.97

Forecast

1Y Price Target

$48.53

Price Target Upside27.37% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering9

EPS Forecast (FY)2.06

Revenue Forecast (FY)$16.86B

Bulls Say, Bears Say

Bulls Say

Innovative Portfolio GrowthRapid growth in Teva’s innovative portfolio is shifting the business toward differentiated products with stronger expansion potential than mature generics. The rising contribution from innovation, supported by higher product guidance, can improve revenue quality and support more durable margin growth.

Strong Cash GenerationSubstantial operating and free cash flow provides Teva with internally generated funding for debt reduction, product investment, and business development. The strong conversion of earnings into cash also supports financial resilience and gives management greater flexibility while the portfolio transformation continues.

Biosimilars PlatformA broad biosimilars portfolio and pipeline create a structural growth avenue that complements Teva’s traditional generic medicines business. Marketed products, pipeline depth, and leading positions in several U.S. products can support scale, recurring launches, and expanding contribution over time.

Bears Say

Generic Medicine Revenue PressureThe loss of generic REVLIMID removed a meaningful prior-year revenue and EBITDA contribution, creating a difficult base for near-term comparisons. Continued competition and fewer high-value launches may keep the core generics business under pressure while innovative products scale.

Elevated LeverageTeva’s debt burden remains a constraint despite improving credit ratings and a stated deleveraging plan. Leverage above the long-term target limits financial flexibility, makes sustained cash generation important, and could restrict the pace of investment or acquisitions if earnings soften.

Approval And Payer-access RiskSeveral growth initiatives depend on regulatory decisions, payer access, and policy outcomes rather than commercial execution alone. Delays, restrictive reimbursement, or changes after IRA implementation could slow product uptake and make the company’s growth and margin targets harder to achieve.

Teva News

Teva price target raised to $47 from $42 at Barclays

Barclays analyst Glen Santangelo raised the firm’s price target on Teva (TEVA) to $47 from $42 and keeps...

13d ago

TEVA

Teva price target raised to $50 from $40 at JPMorgan

JPMorgan raised the firm’s price target on Teva (TEVA) to $50 from $40 and keeps an Overweight rating...

17d ago

TEVA

Midday Fly By: SpaceX buys spectrum, Delta cuts earnings guidance

The major averages were broadly higher near noon as a rebound in tech stocks helps Wall Street bounce...

19d ago

Teva announces FDA approval for Weltruza

Teva (TEVA) announced that the FDA has approved Weltruza for extended-release injectable suspension, a new, once-monthly, subcutaneous long-acting...

19d ago

TEVA

First Tracks Biotherapeutics price target raised to $62 from $55 at Wells Fargo

Wells Fargo raised the firm’s price target on First Tracks Biotherapeutics (TRAX) to $62 from $55 and keeps...

19d ago

ARGX

TEVA

Teva call volume above normal and directionally bullish

Bullish option flow detected in Teva (TEVA) with 7,335 calls trading, 1.2x expected, and implied vol increasing over...

21d ago

TEVA

Teva announces published review on dopamine pathways in Tourette syndrome

Teva (TEVA) Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries, announced that the Journal of Child Neurology published...

26d ago

TEVA

Teva announces new data for ecopipam

Teva (TEVA) Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries, announced new data for ecopipam. Presented at the...

26d ago

TEVA

Exxon Mobil downgraded, BP upgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

27d ago

Teva, Samsung Bioepis expand strategic partnership to advance biosimilars

Samsung Bioepis and Teva (TEVA) Pharmaceutical Industries announced that the companies have entered into a global license, development,...

27d ago

TEVA

Salveen Richter Reiterates Buy on Teva, Sets $50 12-Month Target Backed by EV/EBITDA Valuation Ahead of Q3 Earnings

Analyst Salveen Richter of Goldman Sachs maintained a Buy rating on Teva, with a price target of $50.00....

14d ago

TEVA

Teva Rated Buy on Improving Balance Sheet, Emerging Pipeline, and Modest Upside to Current Share Price

Analyst Jason Gerberry of Bank of America Securities maintained a Buy rating on Teva, with a price target...

1M ago

TEVA

Teva Pharmaceutical Announces New Senior Notes Offering

Teva Pharmaceutical ( ($TEVA) ) has issued an update. On September 16, 2026, Teva’s Dutch finance units issued...

1M ago

TEVA

Safe Pro Group (NASDAQ: SPAI) Draws WhaleWatchAlerts Attention Following Phillip Frost’s $4M Share Purchase

Austin, Texas, United States, September 15th, 2026, FinanceWire Billionaire investor Dr. Phillip Frost purchased 1 million restricted Safe...

1M ago

OPK

SPAI

TEVA FAQ

What was Teva Pharmaceutical Industries Limited’s price range in the past 12 months?

Teva Pharmaceutical Industries Limited lowest stock price was $16.74 and its highest was $42.02 in the past 12 months.

What is Teva Pharmaceutical Industries Limited’s market cap?

Teva Pharmaceutical Industries Limited’s market cap is $47.21B.

When is Teva Pharmaceutical Industries Limited’s upcoming earnings report date?

Teva Pharmaceutical Industries Limited’s upcoming earnings report date is Nov 03, 2026 which is in 6 days.

How were Teva Pharmaceutical Industries Limited’s earnings last quarter?

Teva Pharmaceutical Industries Limited released its earnings results on Jul 29, 2026. The company reported $0.021 earnings per share for the quarter, missing the consensus estimate of $0.052 by -$0.031.

Is Teva Pharmaceutical Industries Limited overvalued?

According to Wall Street analysts Teva Pharmaceutical Industries Limited’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Teva Pharmaceutical Industries Limited pay dividends?

Teva Pharmaceutical Industries Limited pays a Quarterly dividend of $0.085 which represents an annual dividend yield of 5.8%. See more information on Teva Pharmaceutical Industries Limited dividends here

What is Teva Pharmaceutical Industries Limited’s EPS estimate?

Teva Pharmaceutical Industries Limited’s EPS estimate is 0.73.

How many shares outstanding does Teva Pharmaceutical Industries Limited have?

Teva Pharmaceutical Industries Limited has 1,165,296,100 shares outstanding.

What happened to Teva Pharmaceutical Industries Limited’s price movement after its last earnings report?

Teva Pharmaceutical Industries Limited reported an EPS of $0.021 in its last earnings report, missing expectations of $0.052. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Teva Pharmaceutical Industries Limited?

Currently, no hedge funds are holding shares in TEVA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Teva Stock Smart Score

Outperform

Fundamentals

Return on Equity

9.18%

Trailing 12-Months

Asset Growth

-0.68%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited operates as a prominent global pharmaceutical firm, involved in the research, development, manufacturing, marketing, and distribution of generic, specialized, and biopharmaceutical products throughout North America, Europe, and other international regions. The company's diverse portfolio encompasses sterile preparations, hormonal therapies, high-potency drugs, and cytotoxic substances, supplied in a wide array of dosage forms such as tablets, capsules, injectable solutions, inhalants, oral liquids, transdermal patches, topical ointments, and creams. Furthermore, Teva develops, produces, and sells active pharmaceutical ingredients (APIs). A significant portion of its research and product development is concentrated on the central nervous system, pain management, respiratory illnesses, and oncology. Leading products for the central nervous system include Copaxone, utilized for relapsing multiple sclerosis; AJOVY, an option for migraine prevention; and AUSTEDO, prescribed for tardive dyskinesia and chorea linked to Huntington's disease. Within the respiratory domain, addressing asthma and chronic obstructive pulmonary disease, Teva offers products like ProAir, QVAR, various Digihaler and RespiClick formulations, along with BRALTUS and CINQAIR/CINQAERO. Their oncology division features treatments such as Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. The company also collaborates with MedinCell on the creation and commercialization of multiple extended-release injectable products, including a risperidone suspension designed for individuals with schizophrenia. Teva Pharmaceutical Industries Limited was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.

Teva (TEVA) Earnings & Revenues

Historic Earnings Reports

TEVA Revenue Breakdown

54.45% North America

32.42% Europe

13.12% International Markets

TEVA Stock 12 Month Forecast

Average Price Target

$48.53

▲(27.37% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"17":"$17","56":"$56","26.75":"$26.8","36.5":"$36.5","46.25":"$46.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":55,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$55.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":48.528939388888894,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$48.53</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":43,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$43.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[17,26.75,36.5,46.25,56],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,39.31,40.51692307692308,41.723846153846154,42.93076923076923,44.13769230769231,45.34461538461539,46.55153846153846,47.75846153846154,48.965384615384615,50.1723076923077,51.37923076923077,52.58615384615385,53.793076923076924,{"y":55,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,39.31,40.01914918376069,40.72829836752137,41.437447551282055,42.146596735042735,42.85574591880342,43.56489510256411,44.27404428632479,44.983193470085475,45.692342653846154,46.40149183760684,47.11064102136753,47.81979020512821,{"y":48.528939388888894,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,39.31,39.59384615384616,39.87769230769231,40.16153846153846,40.44538461538462,40.72923076923077,41.01307692307692,41.29692307692308,41.580769230769235,41.864615384615384,42.14846153846154,42.432307692307695,42.716153846153844,{"y":43,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":20.01,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.5,"date":1761955200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":26,"date":1764547200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":28.61,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.36,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.36,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.36,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.19,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.19,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.4,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.31,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >